Stay updated with breaking news from Targeted Augmentation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
- Company advancing second TANGO ASO into the clinic - - STK-002 has the potential to be the first disease-modifying therapy to address the root cause of ADOA, the most common inherited optic nerve
- Dosing anticipated to start in the coming weeks - - Company remains on track for its planned data readouts from the Phase 1/2a MONARCH and ADMIRAL studies in... | March 15, 2023
Research from the University of Virginia School of Medicine suggests how a newly developed gene therapy can treat Dravet syndrome, a severe form of epilepsy, and potentially prolong survival for people with the condition.
Read the latest stock market news on MarketBeat. Get real-time analyst ratings, dividend information, earnings results, financials, headlines, insider trades and options data for any stock.
– Data presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting support the Company’s work to advance STK-002 as the first potential disease modifying treatment for Autosomal Dominant Optic Atrophy (ADOA) –– ADOA is the most common inherited optic nerve disorder –BEDFORD, Mass.--(B...